{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:32:14Z","timestamp":1758709934543,"version":"3.44.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","award":["2018A0303130225"],"award-info":[{"award-number":["2018A0303130225"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bioorg.2021.105419","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T11:47:08Z","timestamp":1634125628000},"page":"105419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Discovery of novel ibrutinib analogues to treat malignant melanoma"],"prefix":"10.1016","volume":"117","author":[{"given":"Sumei","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2021.105419_b0005","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/ijms20030608","article-title":"Cirsiliol suppressed epithelial to mesenchymal transition in B16F10 malignant melanoma cells through alteration of the PI3K\/akt\/NF-\u03baB signaling pathway","volume":"20","author":"Prasad","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2021.105419_b0010","first-page":"28","article-title":"Melanoma: genetic abnormalities, tumor progression, clonal evolution and tumor initiating cells","volume":"5","author":"Testa","year":"2017","journal-title":"Med. Sci. (Basel)."},{"issue":"3","key":"10.1016\/j.bioorg.2021.105419_b0015","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molmed.2014.12.007","article-title":"Molecular drivers of cellular metabolic reprogramming in melanoma","volume":"21","author":"Abildgaard","year":"2015","journal-title":"Trends Mol. Med."},{"issue":"7","key":"10.1016\/j.bioorg.2021.105419_b0020","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/bjc.2017.254","article-title":"Tumour mutation status and sites of metastasis in patients with cutaneous melanoma","volume":"117","author":"Adler","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2021.105419_b0025","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4161\/cbt.28555","article-title":"Melanoma immunotherapy","volume":"15","author":"Sanlorenzo","year":"2014","journal-title":"Cancer Bio Ther."},{"issue":"5","key":"10.1016\/j.bioorg.2021.105419_b0030","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1021\/acsptsci.0c00072","article-title":"Development of Ligand-Drug Conjugates Targeting Melanoma through the Overexpressed Melanocortin 1 Receptor","volume":"3","author":"Zhou","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2021.105419_b0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.mcna.2021.04.005","article-title":"Recognition, Staging, and Management of Melanoma","volume":"105","author":"Rashid","year":"2021","journal-title":"Med. Clin. North Am."},{"key":"10.1016\/j.bioorg.2021.105419_b0040","series-title":"Mechanisms of Drug Resistance in Cancer Therapy, Handbook of Experimental Pharmacology, Springer","first-page":"91","article-title":"Mechanisms of Drug Resistance in Melanoma","author":"Winder","year":"2017"},{"key":"10.1016\/j.bioorg.2021.105419_b0045","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1182\/blood.2021011574","article-title":"Ibrutinib: another string to its bow","volume":"137","author":"Stankovic","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2021.105419_b0050","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.3390\/cancers13102468","article-title":"Current Treatment Options in CLL","volume":"13","author":"Bewarder","year":"2021","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.bioorg.2021.105419_b0055","series-title":"Adverse Events and Oncotargeted Kinase Inhibitors","first-page":"57","article-title":"Kinase Inhibitors","author":"Tridente","year":"2017"},{"issue":"5","key":"10.1016\/j.bioorg.2021.105419_b0060","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.4049\/jimmunol.1402304","article-title":"Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase \u03b4 but not SYK or BTK in chronic lymphocytic leukemia cells","volume":"194","author":"Till","year":"2015","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105419_b0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12272-019-01124-1","article-title":"Development of BTK inhibitors for the treatment of B-cell Malignancies","volume":"42","author":"Kim","year":"2019","journal-title":"Arch Pharm Res."},{"issue":"9","key":"10.1016\/j.bioorg.2021.105419_b0070","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic Antitumor Immunity by Checkpoint Blockade Is Enhanced by Ibrutinib, an Inhibitor of Both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2021.105419_b0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2017.06.001","article-title":"Bruton's tyrosine kinase (BTK) as a promising target in solid tumors","volume":"58","author":"Molina-Cerrillo","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bioorg.2021.105419_b0080","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/jcm7040062","article-title":"Novel Indications for Bruton\u2019s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies","volume":"7","author":"Campbell","year":"2018","journal-title":"J Clin Med."},{"issue":"17","key":"10.1016\/j.bioorg.2021.105419_b0085","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/s41388-017-0079-x","article-title":"Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner","volume":"37","author":"Rauf","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2021.105419_b0090","doi-asserted-by":"crossref","first-page":"113329","DOI":"10.1016\/j.ejmech.2021.113329","article-title":"Emerging small-molecule inhibitors of the Bruton\u2019s tyrosine kinase (BTK): Current development","volume":"217","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105419_b0095","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.bioorg.2021.105419_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040620721989588","article-title":"The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia","volume":"12","author":"Gordon","year":"2021","journal-title":"Ther Adv Hematol."},{"issue":"17","key":"10.1016\/j.bioorg.2021.105419_b0105","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105419_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128197","article-title":"Synthesis and antiproliferative screening of novel doubly modified colchicines containing urea, thiourea and guanidine moieties","volume":"47","author":"Krzywik","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2021.105419_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103323","article-title":"Design, synthesis and biological evaluation of some new 1,3,4-thiadiazine-thiourea derivatives as potential antitumor agents against non-small cell lung cancer cells","volume":"93","author":"Ragab","year":"2019","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105419_b0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14756366.2020.1837124","article-title":"Pharmacophore-based virtual screening, synthesis, biological evaluation, and molecular docking study of novel pyrrolizines bearing urea\/thiourea moieties with potential cytotoxicity and CDK inhibitory activities","volume":"36","author":"Shawky","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2021.105419_b0125","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/14756366.2019.1702653","article-title":"Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions","volume":"35","author":"Zhang","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2021.105419_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112363","article-title":"Synthesis and anticancer activity of thiourea derivatives bearing a benzodioxole moiety with EGFR inhibitory activity, apoptosis assay and molecular docking study","volume":"198","author":"Abbas","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2021.105419_b0135","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1021\/acs.jmedchem.9b00191","article-title":"Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model","volume":"62","author":"Farooqi","year":"2019","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2021.105419_b0140","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s00109-016-1475-3","article-title":"Cyclin D1, cancer progression, and opportunities in cancer treatment","volume":"94","author":"Qie","year":"2016","journal-title":"J Mol Med (Berl)."},{"issue":"2","key":"10.1016\/j.bioorg.2021.105419_b0145","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/15384101.2019.1706903","article-title":"The double dealing of cyclin D1","volume":"19","author":"Tchakarska","year":"2020","journal-title":"Cell Cycle"},{"issue":"8","key":"10.1016\/j.bioorg.2021.105419_b0150","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin D as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2021.105419_b0155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","article-title":"Survivin: a unique target for tumor therapy","volume":"16","author":"Garg","year":"2016","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bioorg.2021.105419_b0160","first-page":"1","article-title":"Survivin as a biological biomarker for diagnosis and therapy","author":"Li","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.bioorg.2021.105419_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.matbio.2021.06.002","article-title":"Autophagy: Instructions from the extracellular matrix","author":"Schaefer","year":"2021","journal-title":"Matrix Biol"},{"issue":"7741","key":"10.1016\/j.bioorg.2021.105419_b0170","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41586-019-0885-0","article-title":"Autophagic cell death restricts chromosomal instability during replicative crisis","volume":"565","author":"Nassour","year":"2019","journal-title":"Nature"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821007963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206821007963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:23:57Z","timestamp":1758615837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206821007963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":34,"alternative-id":["S0045206821007963"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105419","relation":{},"ISSN":["0045-2068"],"issn-type":[{"type":"print","value":"0045-2068"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel ibrutinib analogues to treat malignant melanoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2021.105419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105419"}}